← Eichor
Study identifier: NCT04480203 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Coping After Breast Cancer - a Randomized Clinical Trial With Two Digital Interventions

Condition: Breast Cancer Patients · Health, Subjective  ·  Sponsor: Norwegian Institute of Public Health

PhaseNA
Planned participants390
Who can joinFemale, 20 Years to 69 Years
Healthy volunteersNo

About this study

1. Breast cancer patients and age-matched controls are first invited to answer questions on HRQoL. 2. Among responding breast cancer patients, a subset are invited in a randomized clinical trial with two digital interventions for cancer stress management, cognitive based stress management (CBSM) and mindfulness based intervention (MBI), as well as a control group. 3. The goal is to determine whether digital CBSM or MBI can effectively reduce stress levels as compared to a control group. Second, whether these interventions can improve HRQoL (or avoid onset of HRQoL problems) for patients with breast cancer, compared to a control group.

This description comes directly from the study's public registry record.

Talk to the study team

Giske Ursin, MD, PhD  ·  +4722451300  ·  giske.ursin@kreftregisteret.no

Ine M Larsson  ·  +4722928985  ·  ine.marie.larsson@kreftregisteret.no

Always discuss trial participation with your own doctor first.

Locations (1)

Cancer Registry of NorwayOslo, NorwayRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04480203